Intercept: the Warp Speed mindset now takes on the common cold

On average, we spend 5% of our lives fighting off a cold or the flu. The figure, attributed to Nan Ransohoff, the Stripe executive leading the new Intercept initiative, neatly sums up why this venture deserves attention: we have normalized as inevitable something that represents an enormous, silent burden. The nonprofit organization, endowed with 500 million dollars, is launching with funding from Stripe, Anthropic, the OpenAI Foundation, Flu Lab, Bill Gates and operators at Jane Street Capital, with the goal of preventing and, in the long term, eliminating viral respiratory infections.

The starting diagnosis is as much economic as scientific. There are more than 200 viruses capable of causing a cold —rhinoviruses chief among them, according to the American Lung Association— and that diversity makes it unviable for the pharmaceutical industry to develop a vaccine for each one. «When pharmaceutical companies analyze it, it isn't as attractive as other areas», Ransohoff admits. It is the classic market failure: a massive problem that finds no commercial incentives. And it is precisely there that scientific philanthropy can add real value, occupying a space that the private sector, by its own logic, leaves empty.

What makes Intercept different from a simple donation fund is its technical thesis. The idea arose from conversations between Ransohoff and David Veesler, a structural biologist at the University of Washington, who argues that it is now feasible to design broad-spectrum countermeasures against multiple viruses at once, relying on RNA drugs, antibodies and computational protein design. One of the avenues being explored consists of engineering proteins that «trap» viruses, applicable as a nasal spray before infection. «Many of these problems had never been tackled with modern technologies», notes Veesler, who points to inertia as the real enemy: viral diversity is so intimidating that «people don't even try».

The approach, moreover, is not limited to vaccines. Intercept envisions large-scale air purification systems —using high-intensity ultraviolet light— for schools, offices and public spaces. The analogy its promoters use is elegant: just as we treat water before it reaches homes, we could «clean» shared air before pathogens reach people. It is a reminder that the public health of the future will probably combine cutting-edge biology with everyday environmental engineering.

The initiative's credibility rests on its people and its track record. Among the advisers are Peter Marks, a former senior FDA official, and Moncef Slaoui, who led Operation Warp Speed against COVID-19. And Stripe already has experience with such bets: it drove Frontier, a 1.8 billion program for carbon capture, and the Collison brothers contributed 650 million to found the Arc Institute, which has developed AI models for biology. The parallel Ransohoff draws is revealing: like carbon capture, the common cold is «technically possible» to combat but «lacks commercial incentives».

It is worth keeping expectations measured. Eradicating the common cold is, today, an aspiration rather than a promise, and the road between proof of concept and a safe, scalable product is long. But Intercept's merit lies in the approach, not just the goal: it transfers to a chronic problem the «mission impossible that becomes possible» mindset that the pandemic left behind. At a time when the budget of the US NIAID has been stagnant for years at around 6.5 billion annually, seeing players from AI and finance fund risky basic science is, in itself, a healthy sign. Whether they succeed or not, they will have demonstrated something valuable: that it is worth, at the very least, trying.